LOXL1-AS1 predicts poor prognosis and promotes cell proliferation, migration, and invasion in osteosarcoma.
LOXL1-AS1
LncRNA
biomarker
osteosarcoma
Journal
Bioscience reports
ISSN: 1573-4935
Titre abrégé: Biosci Rep
Pays: England
ID NLM: 8102797
Informations de publication
Date de publication:
30 04 2019
30 04 2019
Historique:
received:
21
02
2019
revised:
27
03
2019
accepted:
31
03
2019
pubmed:
5
4
2019
medline:
18
6
2020
entrez:
5
4
2019
Statut:
epublish
Résumé
lncRNA LOXL1 antisense RNA 1 (lncRNA LOXL1-AS1) was recently found to function as oncogenic lncRNA in glioblastoma, prostate cancer, and medulloblastoma. The role of LOXL1-AS1 in osteosarcoma was still unknown. In our study, we found LOXL1-AS1 expression levels were higher in osteosarcoma tissues and cell lines than normal bone tissues and normal osteoblast cell line, respectively. Moreover, high-expression of LOXL1-AS1 was correlated with Enneking stage, tumor size, distant metastasis, histological grade, and overall survival time in osteosarcoma patients. Furthermore, LOXL1-AS1 overexpression acted as an independent poor predictor for overall survival in osteosarcoma patients. The loss-of-function studies showed knockdown of LOXL1-AS1 dramatically inhibited osteosarcoma cell proliferation, migration, and invasion through suppressing PI3K-AKT pathway. In conclusion, LOXL1-AS1 predicts clinical progression and poor prognosis in osteosarcoma patients and functions as oncogenic lncRNA to regulate cell proliferation, cell cycle, migration, and invasion.
Identifiants
pubmed: 30944201
pii: BSR20190447
doi: 10.1042/BSR20190447
pmc: PMC6488861
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
RNA, Long Noncoding
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2019 The Author(s).
Références
Oncol Lett. 2018 Nov;16(5):6228-6237
pubmed: 30405759
PLoS One. 2014 Jan 27;9(1):e85059
pubmed: 24475036
Biochem Biophys Res Commun. 2017 Jul 1;488(3):528-533
pubmed: 28522297
Noncoding RNA. 2018 Mar 08;4(1):
pubmed: 29657304
Int J Cancer. 2019 Aug 15;145(4):1068-1082
pubmed: 30761524
Exp Eye Res. 2017 Jan;154:88-103
pubmed: 27845061
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Gene. 2019 Jan 5;680:1-8
pubmed: 30240881
Mol Cancer. 2017 Jul 24;16(1):129
pubmed: 28738804
J Clin Oncol. 2015 Sep 20;33(27):3029-35
pubmed: 26304877
Biochem Biophys Res Commun. 2018 Oct 28;505(2):561-568
pubmed: 30278884
Crit Rev Oncog. 2015;20(3-4):173-97
pubmed: 26349415
Biosci Rep. 2018 Dec 14;38(6):
pubmed: 30442873
Biomed Pharmacother. 2018 Oct;106:890-895
pubmed: 30119259
Hum Mol Genet. 2015 Nov 15;24(22):6552-63
pubmed: 26307087
J Cell Biochem. 2019 Jun;120(6):9656-9666
pubmed: 30548308
Expert Rev Anticancer Ther. 2018 Jan;18(1):39-50
pubmed: 29210294
Biochem Biophys Res Commun. 2018 Sep 10;503(3):1530-1536
pubmed: 30037433
Front Oncol. 2018 Jan 26;8:4
pubmed: 29435436
J Transl Med. 2014 Aug 21;12:231
pubmed: 25141911
Biochem Biophys Res Commun. 2018 Jun 2;500(2):518-524
pubmed: 29678575
Anal Cell Pathol (Amst). 2018 Jun 27;2018:9275685
pubmed: 30050750
Clin Genet. 2019 May;95(5):558-568
pubmed: 30614523
Clin Chim Acta. 2015 Apr 15;444:182-92
pubmed: 25704303
Mol Neurobiol. 2017 Apr;54(3):2012-2021
pubmed: 26910817
Indian J Med Paediatr Oncol. 2017 Jan-Mar;38(1):33-43
pubmed: 28469335
Mol Ther Nucleic Acids. 2019 Jun 7;16:130-140
pubmed: 30861415
J Cell Mol Med. 2018 May 29;:
pubmed: 29808528